Comparison of Single-Dose of Albuterol Breath Activated Inhaler Versus Albuterol Metered Dose Inhaler in Asthmatics



Status:Completed
Conditions:Asthma, Asthma
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:7 - 70
Updated:1/14/2018
Start Date:January 2007
End Date:October 2008

Use our guide to learn which trials are right for you!

Comparison of Single-Dose Efficacy of Albuterol-HFA-BAI and Albuterol-HFA-MDI in Asthmatics With Poor Inhaler Coordinating Ability

This is a research study designed to compare the single-dose effectiveness of
albuterol-HFA-BAI (breath activated inhaler) and albuterol-HFA-MDI (metered dose inhaler) in
asthmatics with poor inhaler coordinating abilities. Patients must be 7 to 70 years of age to
participate in this study.


Inclusion Criteria:

- Male or females aged 7-70 years old

- Asthma of a minimum of 6 months duration

- Patients who demonstrate poor inhalation/actuation coordination when evaluated with
the AIM -Aerosol Inhalation Monitor.

- Reversible bronchoconstriction of >12% increase in FEV1 with a cumulative dose of 450
mcg of albuterol

- The reversibility (FEV1) of <70% following administration of the initial 90 mcg of
albuterol

- Ability to perform spirometry reproducibly

- Ability to self-perform PEF determinations and report scores on diaries

- Can tolerate withdrawal of applicable medications at screening

- Otherwise healthy individuals

- Non-smokers for at least two years

Exclusion Criteria:

- Allergy or sensitivity to albuterol

- Exposure to investigational drugs within 30 days prior to the screening visit

- Continuous treatment with Beta-blockers, MAO inhibitors, tricyclic antidepressants,
and/or systemic corticosteroids

- Treated with oral or injectable corticosteroids within the six weeks prior to the
screening visit

- Unstable dose regimen of any required antileukotrienes, inhaled corticosteroids and/or
inhaled cromolyn and/or nedocromil

- Inability to tolerate or unwillingness to comply with required washout periods for all
applicable medications

- Hospitalization for acute exacerbation of asthma more than twice in past year

- Treatment in an emergency room or hospitalization for asthmatic symptoms within three
months prior to the screening visit

- An upper respiratory tract infection and/or sinusitis associated with exacerbation of
asthma that is unresolved three weeks prior to the screening visit

- History and/or presence of any clinically significant non-asthmatic acute or chronic
disease

- Known or suspected substance abuse

- Previous enrollment in an IVAX Research-sponsored Albuterol HFA asthma study

- Other criteria apply
We found this trial at
5
sites
Minneapolis, Minnesota 55402
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Huntington Beach, California 92647
?
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Lake Oswego, Oregon 97035
?
mi
from
Lake Oswego, OR
Click here to add this to my saved trials
Lakewood, Colorado 80401
?
mi
from
Lakewood, CO
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73120
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials